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Summary Guidelines for the prescription of long-term oxygen therapy (LTOT) in
hypoxemic COPD patients are based on two landmark studies in which survival was
the primary outcome. Such patients are importantly symptomatic with poor health-
related quality of life (HRQL) but the effect of LTOT on HRQL remains uncertain.
We undertook a prospective longitudinal interventional study of consecutive COPD
patients referred to our regional oxygen service; n ¼ 43 fulfilling criteria and
commenced on LTOT, n ¼ 25 not fulfilling criteria and continued on standard care.
HRQL was measured at baseline, 2 and 6 months.
Both patient groups had severe COPD as defined by mean FEV1o35% predicted. At
baseline the LTOT group demonstrated significantly worse HRQL as defined by the
Chronic Respiratory Questionnaire (CRQ) (fatigue, emotional function, mastery
and total scores), total generic Dartmouth COOP Charts and anxiety domain of the
Hospital Anxiety and Depression scale. Significant improvements in HRQL were noted
at 2 and 6 months in the LTOT group. Conversely the non-LTOT group demonstrated a
progressive decline in HRQL. Using validated criteria for a minimal clinically
significant improvement in CRQ, there were 28 (67%) and 26 (68%) ‘responders’ at 2
and 6 months respectively in the LTOT group.
The introduction of LTOT to patients with severe COPD fulfilling standard criteria
was associated with early significant improvements in HRQL with sustained or further
response at 6 months.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Current guidelines for the prescription for long-
term oxygen therapy (LTOT) for patients with
chronic hypoxia and chronic obstructive pulmonary
disease (COPD) rely on two landmark studies
performed over 20 years ago in which survival was
the primary outcome.1–3 In the Nocturnal Oxygen
Therapy Trial (NOTT) study mortality was as low as
11.9% and 22.4% at 1 and 2 years respectively in the
continuous oxygen arm.1 However, in clinical
practice these survival advantages may not neces-
sarily be achieved. McCallion et al.4 reported a 50%
mortality rate within the first 3 months of LTOT.
Other studies cite 54% mortality at 2 years5 and 60%
mortality at 3 years.6 Our local experience has also
noted a disturbingly high 6 month mortality rate of
33%.7 These high mortality rates are sobering, and
likely reflect the clinical reality of LTOT prescrip-
tion generally. Thus although the merits of LTOTare
well accepted in regard to survival and the validity
of prescribing LTOT in patients with severe COPD
who satisfy rigorous criteria is not in question,
these results do challenge the premise that the
only role of LTOT is to improve survival. The
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negative impact of COPD on health-related quality
of life (HRQL) is substantial8–10 and the use of HRQL
as an appropriate primary outcome measure is no
longer in dispute. Generally, therapy in COPD
remains largely symptomatic and aimed at enhan-
cing life (adding quality to years). These LTOT
patients with severe symptomatic COPD are sig-
nificantly disabled and may rate improvement in
HRQL more highly than any possible, and perhaps
quite small, survival advantage.
Unfortunately HRQL was not a primary outcome
measure in the original landmark studies, albeit
meagre improvements in neuropsychological func-
tion were reported in the NOTT trial.1,11 There was
no improvement in HRQL as captured by the
Sickness Impact Profile, although Jones et al.12
have shown that this instrument is insensitive, and
the lack of a disease-specific tool may have
accounted for the negative result. In the Medical
Research Council trial HRQL was not specifically
assessed.2 Any subsequent studies were disadvan-
taged in that a randomised placebo-controlled
design would have been deemed unethical. The
few longitudinal studies have been non-randomised
and further hampered by deficiencies such as
patient numbers, potential confounders or limita-
tions with HRQL tools. A small study by Lahdensuo
et al.13 attempted only to examine the psychoso-
cial response to LTOT and reported no significant
changes. Subsequently, Okubadejo et al.14 using a
disease-specific HRQL tool were unable to show a
change in HRQL over a 6 month period. However, a
larger study has reported some clinically significant
improvements in HRQL in females, although the
response in males was less convincing.15 There is
evidence that the mode of oxygen delivery may be
influential. A study by Andersson et al.16 demon-
strated that, for patients ambulant outside the
home, HRQL improved with liquid oxygen but
deteriorated with oxygen provided by a concen-
trator and cylinders for ambulation. However liquid
oxygen is more expensive and concentrators remain
widely used for the provision of LTOT. Furthermore,
a considerable proportion of LTOT patients are
known to be housebound and hence not suitable
candidates for an ambulatory supply.17,18 Accord-
ingly considerable uncertainty remains as to
whether LTOT as provided by an oxygen concen-
trator improves HRQL. Conversely, it is important to
ascertain that LTOT does not adversely affect
HRQL.
This prospective longitudinal interventional
study aimed: (1) to determine the changes in HRQL
following introduction of LTOT in COPD patients
who fulfil standard criteria, (2) to examine whether
baseline characteristics are predictive of clinically
significant improvements in HRQL and (3) to
compare these changes in HRQL in patients on
LTOT with that of a group of severe COPD patients
referred over the same period for LTOT but who did
not fulfil criteria for LTOT.
Methods
Figure 1 outlines the study design. Consecutive
patients with COPD referred to our Regional Oxygen
Service for LTOT assessment were invited to
participate. Local Ethics Committee approval was
obtained with signed consent from all participants.
Inclusion criteria:
(i) severe COPD (British Thoracic Society),3
(ii) standard medical management,
(iii) clinically stable at least 2 months.
Exclusion criteria:
(i) substantive comorbidity,
(ii) current smoker,
(iii) inability to complete questionnaires.
Patients were assessed for LTOT using standard
criteria3
(a) PaO2o7.3 kPa (55mmHg) at rest or
(b) PaO2 7.38 kPa (60mmHg) plus significant
pedal oedema, P wave 43mm standard elec-
trocardiograph leads or secondary polycythe-
mia (packed cell volume 40.55).
LTOT group
Defined as fulfilling criteria for LTOT and supplied
with oxygen.
Non-LTOT group
Defined as not fulfilling for LTOT and not supplied
with oxygen.
The LTOT group received standardised instruction
regarding their oxygen therapy (Invacare 5 con-
centrators, Invacare Corp, Elyria, Ohio USA). Flow
was titrated to achieve resting PaO248 kPa
(SaO2490%). Adherence was defined as mean use
of at least 15 h daily (hour-meter). Ambulatory
oxygen was not provided.
Data collection
Arterial blood gases were measured at rest breath-
ing room air for at least 20min. Spirometry was
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performed to ATS standards (R-Model Vitalograph
Limited, Buckingham, England). The 6min walk
test (6MWT) was performed in triplicate on room
air with measures of distance, oxygen saturation
(SpO2) and modified Borg dyspnoea scores.
19 Ques-
tionnaires were administered at each visit, using
the preceding 2 weeks as the indicative period.
Chronic respiratory questionnaire (CRQ)20–22
This validated, repeatable and responsive disease-
specific interviewer-administered instrument has
four domains; dyspnoea, fatigue, emotional func-
tion, and mastery. Each answer is scored from 1 to 7
(7¼ optimal). Responders were defined using vali-
dated criteria for a minimal clinically significant
difference; an improvement of 0.5 in the mean
score of each domain21 equating to a dyspnoea
change of at least 2.5, fatigue 2, emotional
function 3.5 and mastery 2, respectively.
Dartmouth COOP charts (COOP)23
This self-administered generic HRQL instrument has
9 charts; physical function, daily activities, pain,
social activities, social support, feelings, overall
health, quality of life and change in health.
Responses are scored by a 5-point ordinal scale
ranging from 1 to 5 (1¼ optimal).
Hospital anxiety and depression scale
(HAD)24
This is a reliable self-assessment scale used for
evaluating anxiety and depression in the physically
ill, scores ranging from 0 to 21 (0¼ optimal).
Patient expectations
Patient expectations were explored using the
following question; ‘‘Do you think that oxygen will
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Figure 1 Study design and patient group details.
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(has) improved your quality of life?’’ (1¼ strongly
disagree, 2¼ tend to disagree, 3 tend to agree,
4¼ strongly agree).
Statistical analyses
Results are presented as means (standard devia-
tions) or means (95% confidence intervals). Con-
tinuous variables between groups were compared
with Student’s t-test and the w2 or Fisher’s exact
test for categorical variables. Normality was
checked both graphically and with Shapiro–Wilk
statistics. Associations between responder status
and other risk factors were examined using logistic
regression (with responder/non-responder to oxy-
gen as the outcome measure).
Results
A total of 68 patients were recruited; 43 fulfilling
criteria and supplied with LTOT (LTOT group) and 25
not fulfilling LTOT criteria and not supplied with
oxygen (non-LTOT group). Baseline group charac-
teristics were as shown in Table 1. All had severe
COPD, as defined by FEV1 criteria but those
fulfilling LTOT criteria had significantly worse gas
exchange and functional capacity (6MWD). There
were 5 deaths over the 6 months study period in the
LTOT group and none in the non-LTOT group.
Baseline HRQL
The LTOT group demonstrated significantly worse
HRQL at baseline than the non-LTOT group as
defined by the disease-specific CRQ (total and all
domains except dyspnoea), generic COOP total and
the HAD anxiety domain (Table 2).
Change in HRQL at 2 and 6 months
In the LTOT group significant improvements were
seen in all domains of the CRQ by 2 months which at
6 months were either maintained or further
improved (Fig. 2). Improvements demonstrated in
the total COOP and both HAD domains did not reach
statistical significance. Conversely, HRQL measures
in the non-LTOT group, although significantly higher
at baseline than the LTOT group, deteriorated over
the study period such that by 6 months the HRQL of
the 2 groups was not significantly different. No
significant changes were observed in FEV1, resting
PaO2 on air, BMI, or 6MW distance in either group
over the study period.
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Table 1 Baseline characteristics of LTOT group and non-LTOT group.
LTOT group Non-LTOT group P-value
n ¼ 43 n ¼ 25
PaO2 (kPa)
n 6.9 (0.79) 8.8 (0.81) o0.0001
Male 27 (63%) 18 (72%) 0.44
Age (years) 68 (9.8) 70.6 (6.0) 0.19
Caucasian 39 (91%) 25 (100%) 0.29
Smoking (pack years) 36 (23, 55) 40 (35, 54) 0.35
FEV1 (%predicted) 31.7 (16.0) 29.6 (12.66) 0.58
PaCO2 (kPa) 6.5 (1.14) 5.7 (0.72) 0.005
BMI (kg/m2) 24.8 (5.65) 21.6 (4.38) 0.017
6MWD (m)w 251 (112) 331 (125) 0.014
CRQ (disease-specific)
Dyspnoea (5–25) 15.8 (5.49) 17.4 (4.59) 0.20
Fatigue (4–28) 13.2 (4.67) 16.1 (4.64) 0.016
Emotional function (7–49) 30.8 (8.10) 36.0 (7.69) 0.014
Mastery (4–28) 16.7 (6.03) 20.4 (4.79) 0.009
Total (20–140) 76.7 (20.27) 89.8 (17.42) 0.009
COOP (generic)
Total (9–45) 25.6 23.2 0.059
HAD
Anxiety (0–21) 6.7 (4.20) 4.6 (3.45) 0.042
Depression (0–21) 5.4 (3.15) 4.7 (2.90) 0.37
Note higher scores in COOP, HAD indicate worse HRQL higher scores in CRQ indicate better HRQL.
nSelection criterion.
wn ¼ 36; 25 respectively.
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LTOT responders
The proportion of LTOT responders at 2 months
(defined using validated criteria for a minimal
clinically significant improvement) for each domain
of the CRQ were as follows; dyspnoea 35%, fatigue
51%, emotional function 32%, mastery 40%. In total
there were 28 (67%) and 26 (68%) responders at 2
and 6 months, respectively. Generally response at 2
months was predictive of response at 6 months;
only 2 (5%) of responders at 6 months had not
demonstrated a response at 2 months. Conversely 1
(3%) of responders at 2 months did not show
ongoing response at 6 months.
Predictors of LTOT response
Baseline characteristics (gender, resting PaO2 on
air, PaCO2, Borg dyspnoea score, FEV1, 6MWD, CRQ
dyspnoea, emotional function, mastery, fatigue,
total, HAD scores) were not predictive of a
clinically significant improvement in HRQL at 2 or
6 months. The only predictor identified was hours
of oxygen use; every 1 h increase in oxygen use
increased the odds of being a responder by 30%
(odds ratio 1.3, 95% CI 1.06, 1.57, P ¼ 0:01). The
mean use of the oxygen concentrators over a 24 h
period as was 14.6 (3.7) h (using the hour meter).
The proportion of patients using at least 15 h daily
was 60% (n ¼ 25).
Patient expectations regarding LTOT
The majority of patients either agreed 15 (35%) or
strongly agreed 15 (35%) at baseline that LTOT
would improve their HRQL with only 8 (19%)
disagreeing and 2 (5%) strongly disagreeing. Follow-
ing the introduction of LTOTonly 4 patients who had
previously agreed or strongly agreed that oxygen
would improve their HRQL indicated that they now
disagreed or strongly disagreed. Conversely 6
patients who had (strongly) disagreed now
(strongly) agreed that oxygen would improve their
HRQL. Patients’ expectations regarding LTOT were
not predictive of LTOT response.
Discussion
The major finding of this prospective longitudinal
interventional study was the significant improve-
ment in HRQL following the introduction of LTOT to
patients with severe COPD who fulfilled accepted
eligibility criteria. Prior to this study, the results of
a very limited body of work, as summarised earlier,
have been generally unconvincing with regard to
the effect of LTOT on HRQL.
There are very few longitudinal studies which
have examined the effect of HRQL on LTOT possibly
reflecting the logistic difficulties of such studies
and the inability to incorporate a placebo-control
on ethical grounds. Nevertheless this is an impor-
tant question requiring a definitive answer. HRQL is
a important endpoint for patients with severe
symptomatic COPD; it might be argued that such
patients may weight improved HRQL higher than
the possibility of living slightly longer.
However the evidence, up to now, that LTOT is
beneficial with respect to HRQL has not been
compelling. Okubadejo et al.14 using a study design
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Table 2 Changes in health-related quality of life at 2 and 6 months for the LTOT and non-LTOT groups.
LTOT group Non-LTOT group
Change 2 months Change 6 months Change 2 months Change 6 months
n ¼ 42 n ¼ 38 n ¼ 42 n ¼ 38
CRQn
Dyspnoea 2.36 (0.48, 4.23) 2.82 (0.49, 5.15) 0.52 (1.25, 2.29) 0.40 (2.59, 1.79)
Fatigue 2.00 (0.57, 3.43) 1.92 (0.08, 3.77) 0 (1.58, 1.58) 0.16 (1.77, 1.45)
Emotional 2.43 (0.36, 4.50) 2.42 (0.25, 5.10) 0.36 (2.33, 1.61) 1.40 (3.39, 0.59)
Mastery 1.55 (0.21, 2.88) 2.39 (0.94, 3.85) 0.12 (1.04, 1.28) 0.72 (2.27, 0.83)
Total 8.10 (3.02, 13.17) 9.26 (2.37, 16.15) 0.28 (5.98, 5.42) 2.56 (8.31, 3.19)
COOPn
Total 1.45 (3.01, 0.19) 1.03 (2.96, 0.91) 0.32 (2.31, 1.67) 0.20 (1.90, 2.35)
HADn
Anxiety 0.81 (1.71, 0.09) 1.21 (2.30, 0.12) 0.36 (0.82, 1.54) 0.84 (0.31, 1.99)
Depression 0.57 (1.43, 0.29) 1.42 (2.47, 0.37) 0.60 (1.27, 0.07) 0.40 (1.23, 0.43)
nHigher scores in COOP, HAD indicate worse HRQL. Higher scores in CRQ indicate better HRQL.
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similar to that employed in this paper, were unable
to show a change in HRQL (using the disease-
specific Saint George’s Respiratory Questionnaire)
over a 6 month period, although this was a small
study (n ¼ 23) and hence may have been under-
powered. Our study was both larger and employed
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Figure 2 Changes in HRQL by CRQ domain and Hospital Anxiety and Depression scale at 2 and 6 months for the LTOTand
non-LTOT groups.
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the CRQ, an alternative disease-specific tool which
may possibly be more responsive.22 Crockett et al.15
did report clinically significant improvements in
HRQL at 3 months in females, albeit with a less
convincing response in males. Although there is
increasing recognition of gender differences in
response to cigarette smoking, response to other
COPD management strategies, COPD mortality and
possible perception of HRQL, our study did not
support this apparent gender differential.
The absence of a placebo-control is unavoidable.
We fully acknowledge the results from the non-
LTOT group must be interpreted with caution.
However, they were recruited consecutively from
the same COPD population referred for LTOT,
although did not fulfil criteria for LTOT. HRQL
declined in this group despite ongoing standard
optimal care over the 6 month study period
analogous to the decline observed in the ISOLDE
study.25 This strengthens the contention that
improved HRQL in the LTOT group might be directly
ascribable to the introduction of LTOT in that all
other aspects of care were standardised. Our
results were further strengthened by a prospective
design attempting to minimise potential confoun-
ders and inclusion criteria rigorously insisting on a
prolonged period of at least 2 months clinical
stability prior to commencing LTOT. Furthermore
responders were identified using a priori validated
definitions of a clinically important change in
HRQL.
The relatively short time of 2 months to obtain
clinically meaningful improvement in HRQL is
striking, in comparison with the time to show
improvement in survival, i.e. 500 days in the
Medical Research Council study.2 It is also impor-
tant to note that HRQL response at 2 months was
predictive of sustained or improved response at 6
months. Furthermore, although improvement was
relatively modest, it was comparable to other
management strategies accepted as a standard of
care, such as inhaled bronchodilator therapy and
pulmonary rehabilitation.26,27 In a disease with
limited therapeutic options this is of considerable
clinical importance.
The mechanism of benefit to HRQL in response to
LTOT remains to be determined. A recent study
found HRQL to be related to the severity of
hypoxemia in patients with severe COPD.10 It is
certainly plausible that that there is a direct effect
on HRQL from the correction of hypoxia for a
sufficient period. In support of this, our study found
that the only predictor of response to LTOT was
hours of use. Poor sleep quality in association with
frequent arousals seen with desaturation is well
recognised in COPD.28,29 Furthermore, it has been
shown in patients with obstructive sleep apnoea
that changes in daytime function correlate more
closely with degree of nocturnal hypoxemia than
frequency of EEG arousals.30 Hence, although as
yet unproven, correction of nocturnal hypoxia with
oxygen therapy in COPD patients might improve
sleep quality with associated benefit in other HRQL
indices. In our study this may have been indirectly
reflected in domains such as fatigue where indeed a
greater response was noted.
We noted significant improvement in HRQL
despite the potential negative impact of LTOT
therapy which includes not only physical con-
straints but nasal cannulae discomfort. However,
previous work has suggested that reduced indepen-
dence could not be directly attributed to restric-
tion imposed by a concentrator.31 Nevertheless
there is some evidence that mode of oxygen
delivery is significantly influential with respect to
impact on HRQL with liquid oxygen proving superior
to oxygen supplied by concentrators in conjunction
with cylinder use during ambulation.16 The im-
provement in HRQL is in accordance with our recent
randomised controlled study. We demonstrated
that ambulatory oxygen results in significant
improvements in HRQL in COPD patients with
exertional desaturation.32 Ideally LTOT would al-
ways be employed in combination with an ambula-
tory supply for those patients who are ambulant
outside the home. However previous work has
shown that up to 45% of LTOT patients are house-
bound17,18 and thus would not be suitable candi-
dates for an additional ambulatory supply. Hence
the results of our study employing a stationary
concentrator alone are reassuring in regard to
HRQL and will be relevant to the majority of
chronically hypoxic patients. Adherence with LTOT
is commonly less than ideal. A study from Scotland
reported that 44% of patients used their oxygen for
less than 15 h daily.6 Our results were very similar;
40% using their oxygen for less than 15 h daily and a
mean use of 14.6 h. The acceptability and toler-
ability of a therapy such as oxygen are important
considerations which are too often neglected. The
ultimate balance of clinical benefit versus adverse
effect will only be captured if appropriate mea-
sures of HRQL are routinely incorporated into
clinical management.
We have fully acknowledged the limitations
imposed by the lack of a placebo-control; ideally
this study might be performed using a cross-over
design. Admittedly, there is a potentially powerful
placebo response to oxygen therapy and high
patient expectations may be significantly influen-
tial. We therefore included a measure of patient
expectations. The majority of our LTOT patients did
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indeed express positive expectations with respect
to LTOT at baseline. Importantly, however, we did
not find these predictive of HRQL response to LTOT.
Our study, although still relatively small was large
enough to show a significant benefit over a short-
term period. However the effects of LTOT on HRQL
over a longer time period remain to be determined.
LTOT has not been demonstrated to prolong survival
in COPD patients with moderate hypoxemia33 and
hence is not currently prescribed for this group.
However, it is possible that LTOT might improve
HRQL in patients with less severe hypoxia not
currently fulfilling standard criteria for LTOT.
In conclusion this study has demonstrated that
the introduction of LTOT was associated with early
and significant improvements in HRQL and sus-
tained or further response at 6 months. There can
be no argument that this COPD population has very
impaired HRQL and thus any intervention shown to
improve this, even to a modest degree, would be
advantageous. Sole reliance on survival as an
outcome may adversely detract from other poten-
tially important benefits from oxygen therapy. Our
results support the use of disease-specific HRQL as
a primary outcome measure for future studies of
oxygen therapy.
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